Cargando…
Targeting myeloid-derived suppressor cells for cancer therapy
The emergence and clinical application of immunotherapy is considered a promising breakthrough in cancer treatment. According to the literature, immune checkpoint blockade (ICB) has achieved positive clinical responses in different cancer types, although its clinical efficacy remains limited in some...
Autores principales: | Tang, Hongchao, Li, Hao, Sun, Zhijun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Compuscript
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610166/ https://www.ncbi.nlm.nih.gov/pubmed/34403220 http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0806 |
Ejemplares similares
-
Myeloid derived suppressor cells: Targets for therapy
por: Waldron, Todd J., et al.
Publicado: (2013) -
Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy
por: Wang, Yufei, et al.
Publicado: (2020) -
Targeting Myeloid-Derived Suppressor Cells in Ovarian Cancer
por: Mabuchi, Seiji, et al.
Publicado: (2021) -
The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers
por: Ren, Ruiyang, et al.
Publicado: (2023) -
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
por: Law, Andrew M. K., et al.
Publicado: (2020)